Loading...
Header Logo
Keywords
Last Name
Institution

DAVID SANGHYUN HONG

TitleAssociate Professor
InstitutionMD Anderson
DepartmentInvestigational Cancer Therapeutics
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 Mar 14; 21(3):e10348. PMID: 30869638.
      View in: PubMed
    2. de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Mar; 20(3):383-393. PMID: 30745090.
      View in: PubMed
    3. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 Feb 07. PMID: 30733229.
      View in: PubMed
    4. Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst. 2019 Feb 01; 111(2):118-128. PMID: 30561713.
      View in: PubMed
    5. Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2019 Jan 29; 10(9):1011-1013. PMID: 30847029.
      View in: PubMed
    6. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C. Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. Am J Cardiol. 2019 Apr 15; 123(8):1351-1357. PMID: 30765065.
      View in: PubMed
    7. Garrido-Laguna I, Krop I, Burris HA, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 Jan 24. PMID: 30680712.
      View in: PubMed
    8. George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DS. Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clin Cancer Inform. 2018 12; 2:1-14. PMID: 30652565.
      View in: PubMed
    9. Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018 Nov 16; 6(1):119. PMID: 30446007.
      View in: PubMed
    10. Hong DS, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel SM, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Apr 15; 25(8):2403-2413. PMID: 30425090.
      View in: PubMed
    11. Sandoval GM, Shim S, Hong DS, Garrett AS, Quintin EM, Marzelli MJ, Patnaik S, Lightbody AA, Reiss AL. Neuroanatomical abnormalities in fragile X syndrome during the adolescent and young adult years. J Psychiatr Res. 2018 12; 107:138-144. PMID: 30408626.
      View in: PubMed
    12. McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, Lazar AJ, Woodman SE. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol. 2019 Mar; 139(3):728-731. PMID: 30798855.
      View in: PubMed
    13. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018 12; 151(3):407-413. PMID: 30366646.
      View in: PubMed
    14. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270. PMID: 30279957.
      View in: PubMed
    15. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243. PMID: 30237864.
      View in: PubMed
    16. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 Nov; 82(5):877-885. PMID: 30182147.
      View in: PubMed
    17. Green T, Saggar M, Ishak A, Hong DS, Reiss AL. X-Chromosome Effects on Attention Networks: Insights from Imaging Resting-State Networks in Turner Syndrome. Cereb Cortex. 2018 Sep 01; 28(9):3176-3183. PMID: 28981595.
      View in: PubMed
    18. Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 Sep; 82(3):419. PMID: 30014222.
      View in: PubMed
    19. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 Nov; 23(11):1300-1309. PMID: 30139837.
      View in: PubMed
    20. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res. 2018 Aug 15; 24(16):3845-3856. PMID: 30018119.
      View in: PubMed
    21. Kheder ES, Hong DS. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins. Clin Cancer Res. 2018 Dec 01; 24(23):5807-5814. PMID: 29986850.
      View in: PubMed
    22. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848. PMID: 29989021.
      View in: PubMed
    23. Patnaik A, Gordon M, Tsai F, Papadopoulous K, Rasco D, Beeram SM, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 Sep; 82(3):407-418. PMID: 29926131.
      View in: PubMed
    24. Hong D, Balzano L, Fessler JA. Asymptotic performance of PCA for high-dimensional heteroscedastic data. J Multivar Anal. 2018 Sep; 167:435-452. PMID: 30778267.
      View in: PubMed
    25. Park KB, Yoo KF, Yoon M, Hong D. Development of Neurospine Surgery in North Korea: The Contribution of Korean American Neurosurgeons. Neurospine. 2018 Jun; 15(2):111-116. PMID: 29991239.
      View in: PubMed
    26. Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol. 2018; 2018. PMID: 30094412.
      View in: PubMed
    27. Radke JB, Worth D, Hong D, Huang S, Sullivan WJ, Wilson EH, White MW. Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. PLoS Pathog. 2018 05; 14(5):e1007035. PMID: 29718996.
      View in: PubMed
    28. Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS. Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364. PMID: 29189398.
      View in: PubMed
    29. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 2018 May; 66:95-103. PMID: 29730462.
      View in: PubMed
    30. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 May; 118(11):1419-1424. PMID: 29695765.
      View in: PubMed
    31. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899. PMID: 29731991.
      View in: PubMed
    32. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601. PMID: 29654067.
      View in: PubMed
    33. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141. PMID: 29748008.
      View in: PubMed
    34. Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 Jul 15; 24(14):3263-3272. PMID: 29643063.
      View in: PubMed
    35. Aghajanian C, Bell-McGuinn KM, Burris HA, Siu LL, Stayner LA, Wheler JJ, Hong DS, Kurkjian C, Pant S, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs. 2018 12; 36(6):1016-1025. PMID: 29611022.
      View in: PubMed
    36. Hong DS. "Communities" of Conditions: Novel Methods for Classifying Psychiatric Disorders. J Am Acad Child Adolesc Psychiatry. 2018 Apr; 57(4):233-234. PMID: 29588048.
      View in: PubMed
    37. Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050. PMID: 29551775.
      View in: PubMed
    38. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 02 22; 378(8):731-739. PMID: 29466156.
      View in: PubMed
    39. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769. PMID: 29462132.
      View in: PubMed
    40. Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget. 2018 Feb 27; 9(16):12959-12970. PMID: 29560123.
      View in: PubMed
    41. Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922. PMID: 29386574.
      View in: PubMed
    42. Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, Curran MA. Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. Clin Cancer Res. 2018 03 01; 24(5):1138-1151. PMID: 29301830.
      View in: PubMed
    43. Seiler C, Green T, Hong D, Chromik L, Huffman L, Holmes S, Reiss AL. Multi-Table Differential Correlation Analysis of Neuroanatomical and Cognitive Interactions in Turner Syndrome. Neuroinformatics. 2018 01; 16(1):81-93. PMID: 29270892.
      View in: PubMed
    44. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100. PMID: 29254498.
      View in: PubMed
    45. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676. PMID: 29237802.
      View in: PubMed
    46. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963. PMID: 29162825.
      View in: PubMed
    47. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646. PMID: 29159766.
      View in: PubMed
    48. Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607. PMID: 29075985.
      View in: PubMed
    49. Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188. PMID: 29051321.
      View in: PubMed
    50. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423. PMID: 29047029.
      View in: PubMed
    51. Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V. Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10). PMID: 29117359.
      View in: PubMed
    52. Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F. Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017. PMID: 30320296.
      View in: PubMed
    53. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMID: 29082359.
      View in: PubMed
    54. Hong DS. Here/In This Issue and There/Abstract Thinking: The Growing, and Changing, Landscape of Child and Adolescent Mental Healthcare Delivery. J Am Acad Child Adolesc Psychiatry. 2017 09; 56(9):719-720. PMID: 28838572.
      View in: PubMed
    55. Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC, Marchetti D. Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun. 2017 08 04; 8(1):196. PMID: 28775303.
      View in: PubMed
    56. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173. PMID: 29152071.
      View in: PubMed
    57. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Jul 20. PMID: 28729355.
      View in: PubMed
    58. Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017 May; 4(5-6):47-56. PMID: 28781987.
      View in: PubMed
    59. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267. PMID: 28424409.
      View in: PubMed
    60. Schroeder RD, Choi W, Hong DS, McConkey DJ. Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. Oncotarget. 2017 Aug 01; 8(31):51675-51687. PMID: 28881678.
      View in: PubMed
    61. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov. 2017 06; 7(6):558-560. PMID: 28576843.
      View in: PubMed
    62. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656. PMID: 28536309.
      View in: PubMed
    63. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806. PMID: 28430579.
      View in: PubMed
    64. Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017 Aug 29; 8(35):58709-58727. PMID: 28938590.
      View in: PubMed
    65. Mueller A, Hong DS, Shepard S, Moore T. Linking ADHD to the Neural Circuitry of Attention. Trends Cogn Sci. 2017 06; 21(6):474-488. PMID: 28483638.
      View in: PubMed
    66. Cox VL, Bhosale P, Varadhachary GR, Wagner-Bartak N, Glitza IC, Gold KA, Atkins JT, Soliman PT, Hong DS, Qayyum A. Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology. 2017 05; 283(2):314-340. PMID: 28418819.
      View in: PubMed
    67. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8). PMID: 28422758.
      View in: PubMed
    68. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35. PMID: 28428884.
      View in: PubMed
    69. Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS. Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. Clin Cancer Res. 2017 Aug 01; 23(15):4020-4026. PMID: 28377482.
      View in: PubMed
    70. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      View in: PubMed
    71. Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Crit Rev Oncol Hematol. 2017 May; 113:256-267. PMID: 28427515.
      View in: PubMed
    72. Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E, Piha-Paul SA, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SR, Gueorguieva I, Hong DS. A phase 1 study of anti-TGFß receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017 04; 79(4):673-680. PMID: 28280971.
      View in: PubMed
    73. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421. PMID: 28275168.
      View in: PubMed
    74. Hong DS. Here/In This Issue and There/Abstract Thinking: The First Year: Incorporating Maternal Mental Health Into Child Psychiatric Practice. J Am Acad Child Adolesc Psychiatry. 2017 03; 56(3):183-184. PMID: 28219481.
      View in: PubMed
    75. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Apr 20; 35(12):1304-1311. PMID: 28240971.
      View in: PubMed
    76. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017 May; 173:58-66. PMID: 28174090.
      View in: PubMed
    77. Hong D, Qi Y, Liu J, Wang H, Wang L, Qian L. A novel surfactant protein C mutation resulting in aberrant protein processing and altered subcellular localization causes infantile interstitial lung disease. Pediatr Res. 2017 Jun; 81(6):891-897. PMID: 28157837.
      View in: PubMed
    78. Tang C, Welsh JW, Hong D. Phase I Trial: SABR and Ipilimumab-Response. Clin Cancer Res. 2017 01 01; 23(1):321. PMID: 28049161.
      View in: PubMed
    79. Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med. 2016 12 14; 14(1):339. PMID: 27974047.
      View in: PubMed
    80. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017 04; 35(2):180-188. PMID: 27917453.
      View in: PubMed
    81. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444. PMID: 27882721.
      View in: PubMed
    82. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413. PMID: 27852698.
      View in: PubMed
    83. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20. PMID: 27802448.
      View in: PubMed
    84. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215. PMID: 27599876.
      View in: PubMed
    85. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448. PMID: 27748430.
      View in: PubMed
    86. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. PMID: 27589687.
      View in: PubMed
    87. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365. PMID: 27729313.
      View in: PubMed
    88. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569. PMID: 27528724.
      View in: PubMed
    89. Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017 02; 35(1):59-67. PMID: 27687047.
      View in: PubMed
    90. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430. PMID: 27486883.
      View in: PubMed
    91. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551.
      View in: PubMed
    92. Hong DS. Here/In This Issue and There/Abstract Thinking: The Data Revolution Has Arrived, but Are We Ready? A Call to Action for Child Psychiatry. J Am Acad Child Adolesc Psychiatry. 2016 09; 55(9):741-2. PMID: 27566111.
      View in: PubMed
    93. Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016 Nov; 50:35-47. PMID: 27612280.
      View in: PubMed
    94. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631. PMID: 27421137.
      View in: PubMed
    95. Jardim DL, Schwaederle M, Hong DS, Kurzrock R. An appraisal of drug development timelines in the Era of precision oncology. Oncotarget. 2016 Aug 16; 7(33):53037-53046. PMID: 27419632.
      View in: PubMed
    96. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485. PMID: 27466356.
      View in: PubMed
    97. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409. PMID: 27412379.
      View in: PubMed
    98. Wickner PG, Hong D. Immediate Drug Hypersensitivity. Curr Allergy Asthma Rep. 2016 Jul; 16(7):49. PMID: 27333778.
      View in: PubMed
    99. Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, Oton AB, Gomez H, Dafni U, Vallejos C, Zielinski C. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open. 2016; 1(4):e000055. PMID: 27843620.
      View in: PubMed
    100. Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71. PMID: 27286994.
      View in: PubMed
    101. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567.
      View in: PubMed
    102. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404. PMID: 27207774.
      View in: PubMed
    103. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701. PMID: 27197177.
      View in: PubMed
    104. Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. cMET Exon 14 Skipping: From the Structure to the Clinic. J Thorac Oncol. 2016 09; 11(9):1423-32. PMID: 27223456.
      View in: PubMed
    105. Giallombardo M, Taverna S, Alessandro R, Hong D, Rolfo C. Exosome-mediated drug resistance in cancer: the near future is here. Ther Adv Med Oncol. 2016 Sep; 8(5):320-2. PMID: 27583023.
      View in: PubMed
    106. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. PMID: 26933802.
      View in: PubMed
    107. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102. PMID: 27085994.
      View in: PubMed
    108. Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. 2016 Apr 12; 7(15):20293-304. PMID: 26934122.
      View in: PubMed
    109. Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71. PMID: 27044938.
      View in: PubMed
    110. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881. PMID: 26994910.
      View in: PubMed
    111. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7. PMID: 27014780.
      View in: PubMed
    112. Hong DS. Here/In This Issue and There/Abstract Thinking: Wielding Weapons: The Intersection Between Firearms and Child Psychiatry. J Am Acad Child Adolesc Psychiatry. 2016 Mar; 55(3):153-4. PMID: 26903245.
      View in: PubMed
    113. Subbiah V, Hong DS, Meric-Bernstam F. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):E1419-20. PMID: 26917690.
      View in: PubMed
    114. Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504. PMID: 26895621.
      View in: PubMed
    115. Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 Mar; 77(3):575-81. PMID: 26825327.
      View in: PubMed
    116. Green T, Fierro KC, Raman MM, Foland-Ross L, Hong DS, Reiss AL. Sex differences in amygdala shape: Insights from Turner syndrome. Hum Brain Mapp. 2016 Apr; 37(4):1593-601. PMID: 26819071.
      View in: PubMed
    117. Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64. PMID: 26698868.
      View in: PubMed
    118. Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 2015 Dec 15; 6(40):43127-34. PMID: 26503473.
      View in: PubMed
    119. Vishnoi M, Peddibhotla S, Yin W, T Scamardo A, George GC, Hong DS, Marchetti D. The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep. 2015 Dec 03; 5:17533. PMID: 26631983.
      View in: PubMed
    120. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. PMID: 26603258.
      View in: PubMed
    121. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185. PMID: 26582900.
      View in: PubMed
    122. Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou A, Zinner R, Subbiah V, Hou MM, Ramirez P, Ramondetta L, Lu K, Meric-Bernstam F. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract. 2015; 2:10. PMID: 27231570.
      View in: PubMed
    123. Jang JE, Min YH, Yoon J, Kim I, Lee JH, Jung CW, Shin HJ, Lee WS, Lee JH, Hong DS, Kim HJ, Kim HJ, Park S, Lee KH, Jang JH, Chung JS, Lee SM, Park J, Park SK, Ahn JS, Min WS, Cheong JW. Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype. Blood Cancer J. 2015 Oct 16; 5:e358. PMID: 26473530.
      View in: PubMed
    124. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713. PMID: 26474549.
      View in: PubMed
    125. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. PMID: 26330075.
      View in: PubMed
    126. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. PMID: 26164085.
      View in: PubMed
    127. Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26378224.
      View in: PubMed
    128. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. PMID: 26405159.
      View in: PubMed
    129. Hong DS. Here/In This Issue and There/Abstract Thinking: The Secret Lives of Adolescents: Are We Asking the Right Questions? J Am Acad Child Adolesc Psychiatry. 2015 Sep; 54(9):697-8. PMID: 26299287.
      View in: PubMed
    130. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980. PMID: 26310908.
      View in: PubMed
    131. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110. PMID: 26015395.
      View in: PubMed
    132. Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30; 6(21):18693-706. PMID: 26155941.
      View in: PubMed
    133. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):597-603. PMID: 26210681.
      View in: PubMed
    134. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10. PMID: 26169970.
      View in: PubMed
    135. Subbiah V, Bupathi M, Kato S, Livingston A, Slopis J, Anderson PM, Hong DS. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2015; 2(7):646-58. PMID: 26328274.
      View in: PubMed
    136. Green T, Bade Shrestha S, Chromik LC, Rutledge K, Pennington BF, Hong DS, Reiss AL. Elucidating X chromosome influences on Attention Deficit Hyperactivity Disorder and executive function. J Psychiatr Res. 2015 Sep; 68:217-25. PMID: 26228422.
      View in: PubMed
    137. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. PMID: 26054632.
      View in: PubMed
    138. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62. PMID: 26014291.
      View in: PubMed
    139. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20. PMID: 25990659.
      View in: PubMed
    140. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. PMID: 25980577.
      View in: PubMed
    141. Backeljauw PF, Bondy C, Chernausek SD, Cernich JT, Cole DA, Fasciano LP, Foodim J, Hawley S, Hong DS, Knickmeyer RC, Kruszka P, Lin AE, Lippe BM, Lorigan GA, Maslen CL, Mauras N, Page DC, Pemberton VL, Prakash SK, Quigley CA, Ranallo KC, Reiss AL, Sandberg DE, Scurlock C, Silberbach M. Proceedings from the Turner Resource Network symposium: the crossroads of health care research and health care delivery. Am J Med Genet A. 2015 Sep; 167A(9):1962-71. PMID: 25920614.
      View in: PubMed
    142. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9. PMID: 25902899.
      View in: PubMed
    143. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25863335.
      View in: PubMed
    144. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31. PMID: 25822109.
      View in: PubMed
    145. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015 Mar 17; 112(6):1088-97. PMID: 25688736.
      View in: PubMed
    146. Hong DS. Here and there: the art (and science) of psychotherapy. J Am Acad Child Adolesc Psychiatry. 2015 Mar; 54(3):157. PMID: 25721178.
      View in: PubMed
    147. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015 Feb 18; 15:61. PMID: 25886620.
      View in: PubMed
    148. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54. PMID: 25680763.
      View in: PubMed
    149. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-8. PMID: 25669829.
      View in: PubMed
    150. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74. PMID: 25666183.
      View in: PubMed
    151. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888.
      View in: PubMed
    152. Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 2015; 14(21):3434-40. PMID: 26467427.
      View in: PubMed
    153. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383. PMID: 25536104.
      View in: PubMed
    154. Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 2014 Nov 30; 5(22):11154-67. PMID: 25525888.
      View in: PubMed
    155. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553.
      View in: PubMed
    156. Gong Y, Xu CY, Wang JR, Hu XH, Hong D, Ji X, Shi W, Chen HX, Wang HB, Wu XM. Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling. Cell Death Dis. 2014 Nov 27; 5:e1544. PMID: 25429621.
      View in: PubMed
    157. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92. PMID: 25373733.
      View in: PubMed
    158. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24. PMID: 25363205.
      View in: PubMed
    159. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86. PMID: 25323060.
      View in: PubMed
    160. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
      View in: PubMed
    161. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Santini D, Peeters M, Russo A, Pauwels P. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta. 2014 Dec; 1846(2):539-46. PMID: 25444714.
      View in: PubMed
    162. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136.
      View in: PubMed
    163. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63. PMID: 25316815.
      View in: PubMed
    164. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84. PMID: 25253784.
      View in: PubMed
    165. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8. PMID: 25187273.
      View in: PubMed
    166. Hong DS. Here/in this issue and there/abstract thinking: Learning disorders and ADHD: are LDs getting the attention they deserve? J Am Acad Child Adolesc Psychiatry. 2014 Sep; 53(9):933-4. PMID: 25151413.
      View in: PubMed
    167. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9. PMID: 25594061.
      View in: PubMed
    168. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530. PMID: 25587555.
      View in: PubMed
    169. Green T, Chromik LC, Mazaika PK, Fierro K, Raman MM, Lazzeroni LC, Hong DS, Reiss AL. Aberrant parietal cortex developmental trajectories in girls with Turner syndrome and related visual-spatial cognitive development: a preliminary study. Am J Med Genet B Neuropsychiatr Genet. 2014 Sep; 165B(6):531-40. PMID: 25044604.
      View in: PubMed
    170. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091. PMID: 25035212.
      View in: PubMed
    171. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26. PMID: 25087088.
      View in: PubMed
    172. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 2014; 6(1):13. PMID: 25024751.
      View in: PubMed
    173. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. PMID: 24987059.
      View in: PubMed
    174. Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61. PMID: 24950418.
      View in: PubMed
    175. de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014 Dec; 14(6):468-74. PMID: 25065564.
      View in: PubMed
    176. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. PMID: 25003695.
      View in: PubMed
    177. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12. PMID: 24919855.
      View in: PubMed
    178. Zhou J, Hong D, Wang J, Hu Y, Xie X, Fang H. Electronic structure variation of the surface and bulk of a LiNi0.5Mn1.5O4 cathode as a function of state of charge: X-ray absorption spectroscopic study. Phys Chem Chem Phys. 2014 Jul 21; 16(27):13838-42. PMID: 24912501.
      View in: PubMed
    179. Fan D, Zhou X, Li Z, Li ZQ, Duan C, Liu T, Zhang F, Huang Y, Zhang Y, Gao F, Guo Y, Gupta R, Chen G, Enver T, Tang J, Hong D. Stem cell programs are retained in human leukemic lymphoblasts. Oncogene. 2015 Apr 16; 34(16):2083-93. PMID: 24909160.
      View in: PubMed
    180. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8):990-1004. PMID: 24953979.
      View in: PubMed
    181. Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs. 2014 Dec; 32(6):1181-7. PMID: 24879333.
      View in: PubMed
    182. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38. PMID: 24912489.
      View in: PubMed
    183. Jacobs C, Tumati V, Kapur P, Yan J, Hong D, Bhuiyan M, Xie XJ, Pistenmaa D, Yu L, Hsieh JT, Saha D, Kim DW. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):729-35. PMID: 24867541.
      View in: PubMed
    184. Bendell JC, Hong DS, Burris HA, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):125-30. PMID: 24819685.
      View in: PubMed
    185. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55. PMID: 24778042.
      View in: PubMed
    186. Akcakanat A, Hong DS, Meric-Bernstam F. Targeting translation initiation in breast cancer. Translation (Austin). 2014; 2(1):e28968. PMID: 26779407.
      View in: PubMed
    187. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22. PMID: 24764123.
      View in: PubMed
    188. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66. PMID: 24746841.
      View in: PubMed
    189. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. PMID: 24752867.
      View in: PubMed
    190. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55. PMID: 24742900.
      View in: PubMed
    191. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. PMID: 24742823.
      View in: PubMed
    192. Munoz J, Dhillon N, Janku F, Watowich SS, Hong DS. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014 May; 19(5):536-44. PMID: 24705981.
      View in: PubMed
    193. Nam S, Chang HR, Kim KT, Kook MC, Hong D, Kwon CH, Jung HR, Park HS, Powis G, Liang H, Park T, Kim YH. PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene. 2014 Oct 09; 33(41):4941-51. PMID: 24681952.
      View in: PubMed
    194. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8. PMID: 24668327.
      View in: PubMed
    195. Tang C, Jardim DL, Hong D. MET in ovarian cancer: metastasis and resistance? Cell Cycle. 2014; 13(8):1220-1. PMID: 24621499.
      View in: PubMed
    196. Hong DS, Hoeft F, Marzelli MJ, Lepage JF, Roeltgen D, Ross J, Reiss AL. Influence of the X-chromosome on neuroanatomy: evidence from Turner and Klinefelter syndromes. J Neurosci. 2014 Mar 05; 34(10):3509-16. PMID: 24599451.
      View in: PubMed
    197. Hong DS. Here/In this issue and there/abstract thinking: personalized psychiatry: are we almost there? J Am Acad Child Adolesc Psychiatry. 2014 Mar; 53(3):263-4. PMID: 24565352.
      View in: PubMed
    198. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388. PMID: 24586741.
      View in: PubMed
    199. Hong DS, Reiss AL. Cognitive and neurological aspects of sex chromosome aneuploidies. Lancet Neurol. 2014 Mar; 13(3):306-18. PMID: 24556008.
      View in: PubMed
    200. Hong DS, Chen YS, Li Y, Yang HW, Wei LL, Shen BG, Sun JR. Evolution of conduction channel and its effect on resistance switching for Au-WO3-x-Au devices. Sci Rep. 2014 Feb 11; 4:4058. PMID: 24514950.
      View in: PubMed
    201. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203. PMID: 24586081.
      View in: PubMed
    202. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501. PMID: 24435060.
      View in: PubMed
    203. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717.
      View in: PubMed
    204. Subbiah V, Brown RE, McGuire MF, Buryanek J, Janku F, Younes A, Hong D. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget. 2014 Jan 15; 5(1):95-102. PMID: 24395633.
      View in: PubMed
    205. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics. 2014 Jan 09; 6(1):2. PMID: 24401732.
      View in: PubMed
    206. Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol. 2014; 15(5):475-85. PMID: 24846062.
      View in: PubMed
    207. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82. PMID: 24356639.
      View in: PubMed
    208. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. PMID: 25593979.
      View in: PubMed
    209. Lepage JF, Hong DS, Raman M, Marzelli M, Roeltgen DP, Lai S, Ross J, Reiss AL. Brain morphology in children with 47, XYY syndrome: a voxel- and surface-based morphometric study. Genes Brain Behav. 2014 Feb; 13(2):127-34. PMID: 24308542.
      View in: PubMed
    210. Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5. PMID: 24335388.
      View in: PubMed
    211. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72. PMID: 24306314.
      View in: PubMed
    212. Schreckinger M, Walker B, Knepper J, Hornyak M, Hong D, Kim JM, Folbe A, Guthikonda M, Mittal S, Szerlip NJ. Post-operative diabetes insipidus after endoscopic transsphenoidal surgery. Pituitary. 2013 Dec; 16(4):445-51. PMID: 23242859.
      View in: PubMed
    213. Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014 Jun; 32(3):436-44. PMID: 24258465.
      View in: PubMed
    214. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2. PMID: 24365125.
      View in: PubMed
    215. Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8. PMID: 24190980.
      View in: PubMed
    216. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20. PMID: 24153239.
      View in: PubMed
    217. Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71. PMID: 24101145.
      View in: PubMed
    218. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. PMID: 24092809.
      View in: PubMed
    219. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84. PMID: 24089446.
      View in: PubMed
    220. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23. PMID: 24634931.
      View in: PubMed
    221. Hong DS. Child and adolescent psychiatrists are often tasked with the challenge of treating patients in various contexts. J Am Acad Child Adolesc Psychiatry. 2013 Sep; 52(9):885-6. PMID: 23972687.
      View in: PubMed
    222. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013 Oct; 12(10):2167-75. PMID: 23963360.
      View in: PubMed
    223. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. PMID: 23907406.
      View in: PubMed
    224. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84. PMID: 23879247.
      View in: PubMed
    225. Song Y, Choi HS, Kim K, Kim Y, Kim BG, Hong D, Keum B, Chun HJ. A simple novel endoscopic successive suture device: a validation study for closure strength and reproducibility. Endoscopy. 2013 Aug; 45(8):655-60. PMID: 23881806.
      View in: PubMed
    226. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 01; 19(17):4824-31. PMID: 23873691.
      View in: PubMed
    227. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer. 2013 Oct; 49(15):3068-75. PMID: 23867127.
      View in: PubMed
    228. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86. PMID: 23756764.
      View in: PubMed
    229. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8. PMID: 23765114.
      View in: PubMed
    230. Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Invest New Drugs. 2013 Oct; 31(5):1300-6. PMID: 23677653.
      View in: PubMed
    231. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
      View in: PubMed
    232. Lepage JF, Hong DS, Mazaika PK, Raman M, Sheau K, Marzelli MJ, Hallmayer J, Reiss AL. Genomic imprinting effects of the X chromosome on brain morphology. J Neurosci. 2013 May 08; 33(19):8567-74. PMID: 23658194.
      View in: PubMed
    233. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. PMID: 23670029.
      View in: PubMed
    234. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84. PMID: 23800712.
      View in: PubMed
    235. Jain RK, Lee JJ, Hong D, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833. PMID: 23628598.
      View in: PubMed
    236. Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs. 2014 Feb; 32(1):154-9. PMID: 23609829.
      View in: PubMed
    237. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65. PMID: 23576709.
      View in: PubMed
    238. Hong DS, George GC, Iwuanyanwu EC, Tavana B, Falchook GS, Piha-Paul SA, Wheler JJ, Mistry RH, Lei X, Kurzrock R. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol. 2013 Jun; 139(6):963-70. PMID: 23455881.
      View in: PubMed
    239. Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, Hong DS, Kurzrock R. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol. 2013 Mar; 149(3):322-6. PMID: 23552670.
      View in: PubMed
    240. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 05; 108(4):826-30. PMID: 23412108.
      View in: PubMed
    241. Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol. 2013 Sep; 8(3):183-188. PMID: 23400451.
      View in: PubMed
    242. Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63. PMID: 23377373.
      View in: PubMed
    243. Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45. PMID: 23247629.
      View in: PubMed
    244. Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs. 2013 Aug; 31(4):967-73. PMID: 23361621.
      View in: PubMed
    245. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 2013 Mar 20; 31(9):e137-40. PMID: 23358976.
      View in: PubMed
    246. Jain RK, Lee JJ, Hong D, Kurzrock R. Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396. PMID: 23451354.
      View in: PubMed
    247. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27. PMID: 23435217.
      View in: PubMed
    248. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555.
      View in: PubMed
    249. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156.
      View in: PubMed
    250. Yu L, Tumati V, Tseng SF, Hsu FM, Kim DN, Hong D, Hsieh JT, Jacobs C, Kapur P, Saha D. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor. Neoplasia. 2012 Dec; 14(12):1203-12. PMID: 23308052.
      View in: PubMed
    251. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013 Jun; 39(4):375-87. PMID: 23199899.
      View in: PubMed
    252. Hong DS, Bray S, Haas BW, Hoeft F, Reiss AL. Aberrant neurocognitive processing of fear in young girls with Turner syndrome. Soc Cogn Affect Neurosci. 2014 Mar; 9(3):255-64. PMID: 23171616.
      View in: PubMed
    253. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26. PMID: 23179336.
      View in: PubMed
    254. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. PMID: 23143207.
      View in: PubMed
    255. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42. PMID: 23139256.
      View in: PubMed
    256. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84. PMID: 23066039.
      View in: PubMed
    257. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018.
      View in: PubMed
    258. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805. PMID: 22927482.
      View in: PubMed
    259. Lepage JF, Mazaika PK, Hong DS, Raman M, Reiss AL. Cortical brain morphology in young, estrogen-naive, and adolescent, estrogen-treated girls with Turner syndrome. Cereb Cortex. 2013 Sep; 23(9):2159-68. PMID: 22806268.
      View in: PubMed
    260. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6. PMID: 22778314.
      View in: PubMed
    261. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012 Nov; 23(11):2960-3. PMID: 22745218.
      View in: PubMed
    262. Bray S, Hoeft F, Hong DS, Reiss AL. Aberrant functional network recruitment of posterior parietal cortex in Turner syndrome. Hum Brain Mapp. 2013 Dec; 34(12):3117-28. PMID: 22711287.
      View in: PubMed
    263. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82. PMID: 22693357.
      View in: PubMed
    264. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90. PMID: 22689801.
      View in: PubMed
    265. Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012 Dec 15; 118(24):6144-51. PMID: 22674635.
      View in: PubMed
    266. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4. PMID: 22580643.
      View in: PubMed
    267. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033. PMID: 22675430.
      View in: PubMed
    268. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. PMID: 22634319.
      View in: PubMed
    269. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303. PMID: 22537607.
      View in: PubMed
    270. Lopez Guerra JL, Gomez D, Zhuang Y, Hong DS, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e61-7. PMID: 22503522.
      View in: PubMed
    271. Lin CS, Selch MT, Lee SP, Wu JK, Xiao F, Hong DS, Chen CH, Hussain A, Lee PP, De Salles AA. Accelerator-based stereotactic radiosurgery for brainstem metastases. Neurosurgery. 2012 Apr; 70(4):953-8; discussion 958. PMID: 21997541.
      View in: PubMed
    272. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 01; 18(9):2625-31. PMID: 22465830.
      View in: PubMed
    273. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9. PMID: 22452943.
      View in: PubMed
    274. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol. 2012 Aug; 23(8):1963-7. PMID: 22377564.
      View in: PubMed
    275. Lepage JF, Dunkin B, Hong DS, Reiss AL. Impact of cognitive profile on social functioning in prepubescent females with Turner syndrome. Child Neuropsychol. 2013; 19(2):161-72. PMID: 22372383.
      View in: PubMed
    276. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012 Apr 15; 18(8):2326-35. PMID: 22355009.
      View in: PubMed
    277. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473.
      View in: PubMed
    278. Lepage JF, Hong DS, Hallmayer J, Reiss AL. Genomic imprinting effects on cognitive and social abilities in prepubertal girls with Turner syndrome. J Clin Endocrinol Metab. 2012 Mar; 97(3):E460-4. PMID: 22238395.
      View in: PubMed
    279. Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012; 64(2):206-17. PMID: 22229660.
      View in: PubMed
    280. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. 2012; 7(1):e29330. PMID: 22235285.
      View in: PubMed
    281. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 May; 69(5):1117-26. PMID: 22205203.
      View in: PubMed
    282. Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol. 2012 Feb 10; 30(5):e64-8. PMID: 22203760.
      View in: PubMed
    283. Munoz J, Hong D, Kurzrock R. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol. 2012 Jan; 95(1):1-2. PMID: 22170230.
      View in: PubMed
    284. Yamagata B, Barnea-Goraly N, Marzelli MJ, Park Y, Hong DS, Mimura M, Reiss AL. White matter aberrations in prepubertal estrogen-naive girls with monosomic Turner syndrome. Cereb Cortex. 2012 Dec; 22(12):2761-8. PMID: 22172580.
      View in: PubMed
    285. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806. PMID: 22039425.
      View in: PubMed
    286. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. PMID: 21890452.
      View in: PubMed
    287. Hong DS, Dunkin B, Reiss AL. Psychosocial functioning and social cognitive processing in girls with Turner syndrome. J Dev Behav Pediatr. 2011 Sep; 32(7):512-20. PMID: 21743350.
      View in: PubMed
    288. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8. PMID: 21859821.
      View in: PubMed
    289. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol. 2011 Sep 10; 29(26):3547-52. PMID: 21844494.
      View in: PubMed
    290. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91. PMID: 21831956.
      View in: PubMed
    291. Galsky MD, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Ann Oncol. 2012 Apr; 23(4):1037-44. PMID: 21828377.
      View in: PubMed
    292. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8. PMID: 21823111.
      View in: PubMed
    293. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508.
      View in: PubMed
    294. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60. PMID: 21750201.
      View in: PubMed
    295. Hong D, Chen HX, Yu HQ, Wang C, Deng HT, Lian QQ, Ge RS. Quantitative proteomic analysis of dexamethasone-induced effects on osteoblast differentiation, proliferation, and apoptosis in MC3T3-E1 cells using SILAC. Osteoporos Int. 2011 Jul; 22(7):2175-86. PMID: 21060993.
      View in: PubMed
    296. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer. 2011 Sep; 9(1):27-30. PMID: 21700509.
      View in: PubMed
    297. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. PMID: 21606412.
      View in: PubMed
    298. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011 May 17; 8(9):528-39. PMID: 21587219.
      View in: PubMed
    299. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther. 2011 Jul; 10(7):1300-7. PMID: 21571911.
      View in: PubMed
    300. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer. 2011 Nov 15; 117(22):5142-50. PMID: 21538342.
      View in: PubMed
    301. Hong D, Wang Z, Zhang W, Xi J, Lu J, Luan X, Yuan Y. A series of Chinese patients with desminopathy associated with six novel and one reported mutations in the desmin gene. Neuropathol Appl Neurobiol. 2011 Apr; 37(3):257-70. PMID: 20696008.
      View in: PubMed
    302. Bray S, Dunkin B, Hong DS, Reiss AL. Reduced functional connectivity during working memory in Turner syndrome. Cereb Cortex. 2011 Nov; 21(11):2471-81. PMID: 21441396.
      View in: PubMed
    303. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res. 2011 Jun 15; 17(12):4110-8. PMID: 21415223.
      View in: PubMed
    304. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35. PMID: 21339262.
      View in: PubMed
    305. Pandey P, Rayes M, Hong D, Guthikonda M, Xavier A. Endovascular management of a giant aneurysm through saphenous vein graft after extracranial-intracranial bypass: case report and literature review. J Neurointerv Surg. 2011 Dec 01; 3(4):361-3. PMID: 21990469.
      View in: PubMed
    306. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. J Cancer. 2011 Feb 10; 2:81-9. PMID: 21326629.
      View in: PubMed
    307. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252.
      View in: PubMed
    308. Piha-Paul SA, Hong DS, Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J Clin Oncol. 2011 Apr 20; 29(12):e333-5. PMID: 21263090.
      View in: PubMed
    309. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65. PMID: 21216929.
      View in: PubMed
    310. Lepage JF, Dunkin B, Hong DS, Reiss AL. Contribution of executive functions to visuospatial difficulties in prepubertal girls with Turner syndrome. Dev Neuropsychol. 2011; 36(8):988-1002. PMID: 22004020.
      View in: PubMed
    311. Marzelli MJ, Hoeft F, Hong DS, Reiss AL. Neuroanatomical spatial patterns in Turner syndrome. Neuroimage. 2011 Mar 15; 55(2):439-47. PMID: 21195197.
      View in: PubMed
    312. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010 Dec; 9(5):311-4. PMID: 21208846.
      View in: PubMed
    313. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther. 2010 Dec; 9(12):3410-9. PMID: 21159616.
      View in: PubMed
    314. Chen J, Hong D, Wang Z, Yuan Y. A novel PNPLA2 mutation causes neutral lipid storage disease with myopathy (NLSDM) presenting muscular dystrophic features with lipid storage and rimmed vacuoles. Clin Neuropathol. 2010 Nov-Dec; 29(6):351-6. PMID: 21073837.
      View in: PubMed
    315. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 01; 16(23):5883-91. PMID: 20947515.
      View in: PubMed
    316. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2011 Jul; 68(1):247-53. PMID: 20941597.
      View in: PubMed
    317. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94. PMID: 20564148.
      View in: PubMed
    318. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 01; 117(1):77-85. PMID: 20737567.
      View in: PubMed
    319. Xue Y, Zhao ZQ, Hong D, Zhao MY, Zhang YX, Wang HJ, Wang Y, Li JC. Lack of association between MD-2 promoter gene variants and tuberculosis. Genet Mol Res. 2010 Aug 17; 9(3):1584-90. PMID: 20730709.
      View in: PubMed
    320. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug 01; 16(15):4031-7. PMID: 20525754.
      View in: PubMed
    321. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. PMID: 20347123.
      View in: PubMed
    322. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010 Mar 15; 116(6):1582-91. PMID: 20108303.
      View in: PubMed
    323. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97. PMID: 20145187.
      View in: PubMed
    324. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2010 Feb; 10(1):46-51. PMID: 20133258.
      View in: PubMed
    325. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Jan; 65(2):235-41. PMID: 19484470.
      View in: PubMed
    326. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8. PMID: 19903778.
      View in: PubMed
    327. Hong D, Lu W, Ye F, Hu Y, Xie X. Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells. Br J Cancer. 2009 Nov 17; 101(10):1798-804. PMID: 19826423.
      View in: PubMed
    328. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32. PMID: 19820016.
      View in: PubMed
    329. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res. 2009 Jul 15; 15(14):4769-76. PMID: 19584162.
      View in: PubMed
    330. Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol. 2009 Jul; 84(7):408-13. PMID: 19437507.
      View in: PubMed
    331. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009 Jul 20; 27(21):3557-65. PMID: 19546406.
      View in: PubMed
    332. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs. 2010 Oct; 28(5):634-40. PMID: 19499186.
      View in: PubMed
    333. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009 Jun 01; 15(11):3881-8. PMID: 19470736.
      View in: PubMed
    334. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer. 2009 Mar 01; 115(5):1091-9. PMID: 19165805.
      View in: PubMed
    335. Hong D, Scaletta Kent J, Kesler S. Cognitive profile of Turner syndrome. Dev Disabil Res Rev. 2009; 15(4):270-8. PMID: 20014362.
      View in: PubMed
    336. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008 Oct 01; 14(19):6296-301. PMID: 18829512.
      View in: PubMed
    337. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008 Jun; 144(6):779-82. PMID: 18559769.
      View in: PubMed
    338. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther. 2008 May; 7(5):1001-6. PMID: 18445656.
      View in: PubMed
    339. Hashemi B, Shaw RJ, Hong DS, Hall R, Nelson K, Steiner H. Posttraumatic stress disorder following traumatic injury: narratives as unconscious indicators of psychopathology. Bull Menninger Clin. 2008; 72(3):179-90. PMID: 18990054.
      View in: PubMed
    340. Hong DS, Bernstein M, Smith C, Gans H, Shaw RJ. Eosinophilic meningoencephalitis: psychiatric presentation and treatment. Int J Psychiatry Med. 2008; 38(3):287-95. PMID: 19069573.
      View in: PubMed
    341. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007 Nov 01; 110(9):1911-28. PMID: 17849470.
      View in: PubMed
    342. Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, Shao Y, Zagzag D. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo. Anticancer Drugs. 2007 Sep; 18(8):875-82. PMID: 17667592.
      View in: PubMed
    343. Hong D, Ye F, Chen H, Lü W, Cheng Q, Hu Y, Xie X. Distribution of human papillomavirus genotypes in the patients with cervical carcinoma and its precursors in Zhejiang Province, China. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):104-9. PMID: 17466048.
      View in: PubMed
    344. Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat SR, Kurzrock R. Improving the institutional submission and approval process for clinical research protocols in oncology. J Clin Oncol. 2007 Apr 20; 25(12):1632-3. PMID: 17443009.
      View in: PubMed
    345. Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006 Sep 15; 107(6):1383-90. PMID: 16902987.
      View in: PubMed
    346. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006 Mar; 168(3):962-72. PMID: 16507911.
      View in: PubMed
    347. Hong D, Jaron D, Buerk DG, Barbee KA. Heterogeneous response of microvascular endothelial cells to shear stress. Am J Physiol Heart Circ Physiol. 2006 Jun; 290(6):H2498-508. PMID: 16415079.
      View in: PubMed
    348. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6. PMID: 16118804.
      View in: PubMed
    349. Hong D, Barbee KA, Buerk DG, Jaron D. Heterogeneous cytoplasmic calcium response in microvascular endothelial cells. Conf Proc IEEE Eng Med Biol Soc. 2005; 7:7493-6. PMID: 17282014.
      View in: PubMed
    350. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85. PMID: 15386332.
      View in: PubMed
    351. Hong DS, Jacobson KL, Raad II, de Lima M, Anderlini P, Fuller GN, Ippoliti C, Cool RM, Leeds NE, Narvios A, Han XY, Padula A, Champlin RE, Hosing C. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis. 2003 Oct 15; 37(8):1044-9. PMID: 14523768.
      View in: PubMed
    352. Lee NS, Cheong HJ, Kim SJ, Kim SE, Kim CK, Lee KT, Park SK, Baick SH, Hong DS, Park HS, Won JH. Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. Leukemia. 2003 Jul; 17(7):1375-83. PMID: 12835727.
      View in: PubMed
    353. Hong D, Lovrics P. Soft-tissue images. Portal vein thrombosis and gas formation: unusual presentation of colon cancer. Can J Surg. 2001 Apr; 44(2):90-1. PMID: 11308242.
      View in: PubMed
    354. Tabet J, Hong D, Kim CW, Wong J, Goodacre R, Anvari M. Laparoscopic versus open bowel resection for Crohn's disease. Can J Gastroenterol. 2001 Apr; 15(4):237-42. PMID: 11331925.
      View in: PubMed
    355. Bae SB, Lee KK, Kim JS, Lee JH, Lee NS, Lee GT, Park SK, Won JH, Baick SH, Hong DS, Lee DW, Park HS. A case of malignant proliferating trichilemmoma of the scalp with multiple metastases. Korean J Intern Med. 2001 Mar; 16(1):40-3. PMID: 11417304.
      View in: PubMed
    356. Hong D, Tabet J, Anvari M. Laparoscopic vs. open resection for colorectal adenocarcinoma. Dis Colon Rectum. 2001 Jan; 44(1):10-8; discussion 18-9. PMID: 11805558.
      View in: PubMed
    357. Dyce O, Bruno JR, Hong D, Silverstein K, Brown MJ, Mirza N. Tongue piercing. The new "rusty nail"? Head Neck. 2000 Oct; 22(7):728-32. PMID: 11002330.
      View in: PubMed
    358. Hong D, Gao M, Mu Y, Cai X, Bryner U. [Intraoperative endoscopic sphincterotomy for common bile duct stones during laparoscopic cholecystectomy]. Zhonghua Wai Ke Za Zhi. 2000 Sep; 38(9):677-9. PMID: 11832137.
      View in: PubMed
    359. Won JH, Cho SD, Park SK, Lee GT, Baick SH, Suh WS, Hong DS, Park HS. Thrombopoietin is synergistic with other cytokines for expansion of cord blood progenitor cells. J Hematother Stem Cell Res. 2000 Aug; 9(4):465-73. PMID: 10982244.
      View in: PubMed
    360. Kim YM, Lee KK, Oh HS, Park SK, Won JH, Hong DS, Park HS, Park JS, Lee DW. Myelomatous effusion with poor response to chemotherapy. J Korean Med Sci. 2000 Apr; 15(2):243-6. PMID: 10803706.
      View in: PubMed
    361. Chen J, Wen A, Hong D. [Changes and significance of concentrations of serum vascular endothelial growth factor in patients with pregnancy induced hypertension]. Zhonghua Fu Chan Ke Za Zhi. 2000 Feb; 35(2):72-4. PMID: 11809101.
      View in: PubMed
    362. Gao L, Chen W, Jiang W, Ge S, Hong D, Wang X. Genetic erosion in northern marginal population of the common wild rice Oryza rufipogon Griff. and its conservation, revealed by the change of population genetic structure. Hereditas. 2000; 133(1):47-53. PMID: 11206853.
      View in: PubMed
    363. Yamaguchi M, McSweeney PA, Kimball L, Gersuk G, Hong DS, Kwok W, Storb R, Beckham C, Deeg HJ. Recognition of major histocompatibility complex class II antigens by two anti-HLA-DR monoclonal antibodies on canine marrow cells correlates with effects on in vitro and in vivo hematopoiesis. Transplantation. 1999 Oct 27; 68(8):1161-71. PMID: 10551646.
      View in: PubMed
    364. Cai X, Wang X, Hong D, Li L, Li J. [The application of intraoperative cholangiography in laparoscopic cholecystectomy]. Zhonghua Wai Ke Za Zhi. 1999 Jul; 37(7):427-8. PMID: 11829880.
      View in: PubMed
    365. Villarreal FJ, Hong D, Omens J. Nicotine-modified postinfarction left ventricular remodeling. Am J Physiol. 1999 03; 276(3):H1103-6. PMID: 10070098.
      View in: PubMed
    366. Gong X, Hong D, Chen S, Shen L, Li P, Yan C. Isolation and characterization of five rice telomere-associated sequences. Sci China C Life Sci. 1998 Aug; 41(4):372-80. PMID: 18726253.
      View in: PubMed
    367. Liang SH, Hong D, Clarke MF. Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J Biol Chem. 1998 Jul 31; 273(31):19817-21. PMID: 9677415.
      View in: PubMed
    368. Han KJ, Jung IS, Kim CK, Park SK, Kim DW, Baick SH, Won JH, Hong DS, Hwang SD, Moon C, Park HS. A case of CMV disease of the jejunum in a patient with non-Hodgkin's lymphoma. Korean J Intern Med. 1998 Jul; 13(2):143-6. PMID: 9735673.
      View in: PubMed
    369. Wang X, Zou Y, Zhang D, Hong D, Liu Z. Genetic diversity analysis by RAPD inCathaya argyrophylla Chun et Kuang. Sci China C Life Sci. 1997 Apr; 40(2):145-51. PMID: 18726310.
      View in: PubMed
    370. Yoon SG, Cho ST, Park SK, Won JH, Baick SH, Hong DS, Park HS. A case of coagulation factor V deficiency complicated with intracranial hemorrhage. Korean J Intern Med. 1997 Jan; 12(1):80-3. PMID: 9159044.
      View in: PubMed
    371. Lee NS, Cha SW, Hong SJ, Shin WY, Lee GT, Jeon JW, Won JH, Baick SH, Hong DS, Park HS. A case of lymphomatoid papulosis occurred simultaneously with Ki-1-positive anaplastic large cell lymphoma. Korean J Intern Med. 1997 Jan; 12(1):84-8. PMID: 9159045.
      View in: PubMed
    372. Huss R, Hong DS, McSweeney PA, Hoy CA, Deeg HJ. Differentiation of canine bone marrow cells with hemopoietic characteristics from an adherent stromal cell precursor. Proc Natl Acad Sci U S A. 1995 Jan 31; 92(3):748-52. PMID: 7531340.
      View in: PubMed
    373. Chang JM, CHen WC, Hong D, Lin JK. The inhibition of DMBA-induced carcinogenesis by neoxanthin in hamster buccal pouch. Nutr Cancer. 1995; 24(3):325-33. PMID: 8610051.
      View in: PubMed
    374. Nakaar V, Dare AO, Hong D, Ullu E, Tschudi C. Upstream tRNA genes are essential for expression of small nuclear and cytoplasmic RNA genes in trypanosomes. Mol Cell Biol. 1994 Oct; 14(10):6736-42. PMID: 7523857.
      View in: PubMed
    375. Hong D, Forsberg NE. Effects of serum and insulin-like growth factor I on protein degradation and protease gene expression in rat L8 myotubes. J Anim Sci. 1994 Sep; 72(9):2279-88. PMID: 8002447.
      View in: PubMed
    376. Hong DS, Deeg HJ. Hemopoietic stem cells: sources and applications. Med Oncol. 1994; 11(2):63-8. PMID: 7850265.
      View in: PubMed
    377. Kim KU, Kim JK, Won JH, Hong DS, Park HS. Acute appendicitis in patients with acute leukemia. Korean J Intern Med. 1993 Jan; 8(1):40-5. PMID: 8268146.
      View in: PubMed
    378. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 14:3434-3440.
    379. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. Journal of Translational Medicine. 14.
    380. Erratum to. Cancer Chemotherapy and Pharmacology. 1.
    381. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology. 1-5.
    382. Targets by organ site.
    383. Corrigendum to "Liquid biopsies in lung cancer. Biochimica et Biophysica Acta - Reviews on Cancer. 1855:17.
    384. An appraisal of drug development timelines in the Era of precision oncology. Oncotarget. 7:53037-53046.
    385. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.
    386. This changes everything, twice!. Science Translational Medicine. 3.
    387. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clinical Cancer Research. 21:4801-4810.
    388. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 7:67521-67531.
    389. Targets by organ site.
    390. Mutation profiling in cholangiocarcinoma. PLoS One. 9.
    391. Good ideas come in small packages. Science Translational Medicine. 3.
    392. RNA-targeted therapeutics in cancer clinical trials. Cancer Treatment Reviews. 50:35-47.
    393. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults. Oncoscience. 1:522-530.
    394. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational New Drugs. 1-9.
    395. MET nucleotide variations and amplification in advanced ovarian cancer. Oncoscience. 1:5-13.
    396. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2:646-652.
    397. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:E1419-E1420.
    398. Survival of patients with metastatic leiomyosarcoma. Cancer Medicine. 5:3437-3444.
    399. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatmentwith themammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist. 20:737-741.
    400. A fountain of cancer. Science Translational Medicine. 3.
    401. Erratum. Journal of the National Cancer Institute. 108.
    402. Phase i study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. Journal of Clinical Oncology. 34:1764-1771.
    403. Exosome-mediated drug resistance in cancer. Therapeutic Advances in Medical Oncology. 8:320-322.
    404. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Archives of Dermatological Research. 1-9.
    405. The mutation that broke the cell's back. Science Translational Medicine. 4.
    406. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 6:20099-20110.
    407. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. Journal of Cancer. 2:81-89.
    408. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. 7:20293-20304.
    409. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clinical Epigenetics. 6.
    410. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6.
    411. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs. 33:621-631.
    412. Targets by organ site.
    413. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 1-6.
    414. Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]. Oncotarget. 6:24581.
    415. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 7:967-980.
    416. Erratum. Cancer. 115:1588.
    417. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    418. Cancer therapy directed by comprehensive genomic profiling. Cancer Research. 76:3690-3701.
    419. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 6:26886-26894.
    420. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 7:64421-64430.
    421. Targets by organ site.
    422. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clinical Epigenetics. 6.
    423. Cancer. Science Translational Medicine. 3.
    424. Graft-versus-host disease. Science Translational Medicine. 3.
    425. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    426. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.
    427. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 6:43127-43134.
    428. The isolation and characterization of CTC subsets related to breast cancer dormancy. Scientific Reports. 5.
    429. Lung cancer. Science Translational Medicine. 3.
    430. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology. 78:167-171.
    431. CMET Exon 14 Skipping. Journal of Thoracic Oncology. 11:1423-1432.
    432. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (Switzerland).
    433. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 122:3401-3409.
    434. Targets by organ site.
    435. Another reason to exercise. Science Translational Medicine. 3.
    436. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials. Investigational New Drugs. 1-9.
    437. Targets by organ site.
    438. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 6:18693-18706.
    439. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.
    440. Patient, heal thyself. Science Translational Medicine. 3.
    441. International Journal of Cancer. 140:208-215.
    442. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 1:540-549.
    443. A hair-raising finding in leukemia. Science Translational Medicine. 3.
    444. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 33:2753-2762.
    445. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    446. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma. Oncotarget. 6:28453-28462.
    447. Axitinib for the first line therapy of renal cancer. Translational Cancer Research. 3:558-561.
    448. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6:12809-12821.
    449. First-in-human phase i study of GSK2126458, an oral pan-class i phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clinical Cancer Research. 22:1932-1939.
    450. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investigational New Drugs.
    451. Glioma. Science Translational Medicine. 3.
    452. Another window of opportunity. Science Translational Medicine. 4.
    453. MET amplification in metastatic colorectal cancer. Oncotarget. 7:54627-54631.
    454. TP53 alterations correlate with response to VEGF/VEGFR inhibitors. Molecular Cancer Therapeutics. 15:2475-2485.
    455. Old dogs and new tricks. Science Translational Medicine. 3.
    456. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discovery. 6:1352-1365.
    457. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. Journal of Clinical Oncology. 34:3562-3569.
    HONG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description